Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Accumulated Expenses (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Accumulated Expenses for 8 consecutive years, with $192000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 85.6% to $192000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $192000.0 through Dec 2025, down 85.6% year-over-year, with the annual reading at $192000.0 for FY2025, 85.6% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $192000.0 at Whitehawk Therapeutics, down from $1.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $14.9 million in Q4 2022, with the low at $31701.0 in Q2 2021.
  • Average Accumulated Expenses over 5 years is $7.8 million, with a median of $8.7 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses skyrocketed 27195.67% in 2022, then tumbled 90.68% in 2024.
  • Over 5 years, Accumulated Expenses stood at $8.7 million in 2021, then surged by 71.46% to $14.9 million in 2022, then fell by 4.13% to $14.3 million in 2023, then crashed by 90.68% to $1.3 million in 2024, then plummeted by 85.6% to $192000.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $192000.0, $1.8 million, and $5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.